Data Visualization and Analysis Software Enables Real-Time Manufacturing Intelligence

Article

MilliporeSigma’s Bio4C Software Suite combines process control, analytics, and plant-level automation.

MilliporeSigma, the Life Science business of Merck KGaA, launched the next component of its BioContinuum Platform, the Bio4C Software Suite, the company announced in an April 30, 2020 press release. The software combines process control, analytics, and plant-level automation, which allows users to look across the entire manufacturing process, rather than only individual operational units.

The company said that an emerging solution to getting biopharmaceutical products to market faster is the integration of software, automation, and analytics into biomanufacturing facilities’ operations to intensify biologic production, with a vision toward connected and continuous processing. The company’s BioContinuum Platform is a driver in the industry journey toward digitalization of the next generation of bioprocessing to increase speed and lower costs.

The new software suite was designed based on the company’s “4C strategy”: control, connect, collect, and collaborate. “Control is the basis of everything MilliporeSigma does to run all of its systems. Connect refers to making digital connections between different process steps and giving that visibility to the entire process. Collect is the ability to gather all data into one place and maintain and validate the integrity of that data. Collaborate is how MilliporeSigma will deliver these technologies to its customers in real time,” said the company in the press release.

Bio4C ProcessPad, part of the “Collect” dimension of the Bio4C Suite, is a browser-based platform that allows users to acquire, aggregate, and analyze data from disparate sources such as equipment, batch records, databases, and historians across the bioprocess. The company says it will roll out further Bio4C Software Suite products and modules throughout 2020 and into the future.

Source: MilliporeSigma

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.